CRDF Stock Price, Chart, Stats & News
Cardiff Oncology, Inc. (CRDF) does not currently pay a dividend.
CRDF chart
Fundamentals
Gross margin | -1890.39% |
Operating margin | -8256.32% |
Pretax margin | -7732.21% |
Net margin | -7732.21% |
Effective tax rate | – |
ROA | -74.09% |
ROE | -82.00% |
D/E | 0.02x |
Interest coverage ratio | – |
CRDF valuation
P/E | – |
P/S | 178.69x |
P/B | 2.28x |
P/CF | -2.73x |
P/FCF | -2.79x |
P/OCF | -2.73x |
PEG | -0.13x |
EV multiple | -2.63x |
About
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer.
Similar securities
Based on sector and market capitalization
